Literature DB >> 17136969

The MCID of the transition dyspnea index is a total score of one unit.

Donald A Mahler1, Theodore J Witek.   

Abstract

The Baseline (BDI) and Transition (TDI) Dyspnea Indexes provide interview-based measurements of breathlessness related to activities of daily living. The BDI is a discriminative instrument that includes specific criteria for each of three components at a single point in time. The TDI is an evaluative instrument that includes specific criteria for each of three components to measure changes from a baseline state. Observational studies have shown that patients with COPD generally experience a gradual progression of breathing difficulty as measured by the TDI over time. Randomized controlled trials have demonstrated excellent measurement characteristics of the TDI; these include responsiveness (ability to detect change) and construct validity (a change in the TDI correlates with changes in other variables). Supporting evidence for one unit as the minimal clinically important difference (MCID) of the TDI is based on: expert preference; use of the physician's global evaluation score as an anchor; and distribution estimates (standard error of measurement and 0.5 of the standard deviation). As an alternative to the interview process, self-administered computerized (SAC) versions of the BDI/TDI have been developed to provide direct patient-reported ratings of dyspnea. To further establish the MCID of the interview-administered and/or the SAC TDI, we recommend that a patient's report of global ratings of change by used as an independent standard or anchor.

Entities:  

Mesh:

Year:  2005        PMID: 17136969     DOI: 10.1081/copd-200050666

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  56 in total

1.  Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.

Authors:  Christine de la Loge; Béatrice Tugaut; Fatoumata Fofana; Jérémy Lambert; Michael Hennig; Uta Tschiesner; Mitra Vahdati-Bolouri; Afisi Segun Ismaila; Yogesh Suresh Punekar
Journal:  Chronic Obstr Pulm Dis       Date:  2016-03-15

Review 2.  QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.

Authors:  James E Frampton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

3.  The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea.

Authors:  David C Currow; Stephen Quinn; Aine Greene; Janet Bull; Miriam J Johnson; Amy P Abernethy
Journal:  J Palliat Med       Date:  2013-06-08       Impact factor: 2.947

Review 4.  Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations.

Authors:  Thomas Glaab; Claus Vogelmeier; Roland Buhl
Journal:  Respir Res       Date:  2010-06-17

5.  ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.

Authors:  Stephen I Rennard; Paul D Scanlon; Gary T Ferguson; Ludmyla Rekeda; Brian T Maurer; Esther Garcia Gil; Cynthia F Caracta
Journal:  Clin Drug Investig       Date:  2013-12       Impact factor: 2.859

Review 6.  Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.

Authors:  Fa-Ming Jiang; Zong-An Liang; Qiao-Ling Zheng; Rong-Chun Wang; Jian Luo; Chun-Tao Li
Journal:  Lung       Date:  2013-01-10       Impact factor: 2.584

7.  [The effect of one year outpatient pulmonary rehabilitation on patients with COPD].

Authors:  Ralf H Zwick; Otto C Burghuber; Natasa Dovjak; Sylvia Hartl; Wolfgang Kössler; Alfred Lichtenschopf; Rudolf Müller; Hartmut Zwick
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

8.  The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Authors:  Donald A Mahler; Edward Kerwin; Lindsey Murray; Carole Dembek
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

9.  Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.

Authors:  Claus F Vogelmeier; Ian P Naya; François Maltais; Leif Bjermer; Edward M Kerwin; Lee Tombs; Paul W Jones; Chris Compton; David A Lipson; Isabelle H Boucot
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-03

10.  Pain in Veterans with COPD: relationship with physical activity and exercise capacity.

Authors:  Rebecca A Raphaely; Maria A Mongiardo; Rebekah L Goldstein; Stephanie A Robinson; Emily S Wan; Marilyn L Moy
Journal:  BMC Pulm Med       Date:  2021-07-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.